2001 - Basel - Switzerland

Thursday June 7
08:00-08:45	Registration and coffee
08:40-09:00	Welcome and Introduction
	James Shannon, Director of Clinical Research and Development, Novartis
	Oral session I	Physiologically-Based Pharmacokinetics	chair: Amy Racine / Mick Looby
09:00-09:30	Ryosei Leo Kawai	Impact of PK variables assessed by physiologically-based PK models
09:30-10:00	Ivan Nestorov	Sensitivity analysis of PBPK and PK/PD models
10:00-10:20	Fredrik Jonsson	Contributed paper (1): Physiologically based pharmacokinetic modeling in risk assessment - Development of Bayesian population methods
10:20-12:10	Coffee Poster and Software session I
	Posters with even numbers are accompanied by their presenter
	Tutorial		chair: Amy Racine / Mick Looby
12:10-12:50	Joe Schafer	Multiple Imputation for Missing data problems
12:50-14:20	Lunch
	Oral session II	Disease progression modelling	chair: Oscar della Pasqua
14:20-15:00	Paolo Vicini	Integrated system models to understand disease status, progression and therapy: case studies
15:00-15:20	Julie Simpson	The natural progression of P.falciparum malaria: Investigation of a historical cohort of syphilis patients treated with malariatherapy
15:20-15:40	Mats Karlsson	Models for sedation scores in acute stroke patients
15:40-16:00	Nick Holford	Auckland bones and summer sun.
16:00-16:20	Tea and Software
	Oral session III	Contributed papers	chair: Peter Milligan
16:20-16:40	Philip Jacqmin	Contributed paper (2): Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model
16:40-17:00	Timothy Goggin	Contributed paper (3): Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug
17:00-18:00	Planning of future PAGE meetings & organization
	Coordinated by Mats Karlsson, Pascal Girard, Jakob Schenker, Jean-Louis Steimer
	For all those interested
19:00-24:00	Social Evening
	at Safranzunft, Gerbergasse (close to Marktplatz), Basel
Friday June 8
	Oral session IV	Contributed papers	chair: France Mentre
09:00-09:20	Lewis Sheiner	Contributed paper (4): Dealing with Missing Data in Longitudinal Studies through Modeling
09:20-09:40	Gordon Graham	Contributed paper (5): Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
09:40-10:00	James Wright	Contributed paper (6): Forward selection and other recipes for disaster
10:00-11:50	Coffee Poster and Software session II
	Posters with uneven/odd numbers are accompanied by their presenter
	Oral session V	Contributed papers	chair: Janet Wade
11:50-12:10	Hui Kimko	Contributed paper (7): Iron kinetics: when drug loss by sampling is critical in data analysis
12:10-12:30	Philip Lowe	Contributed paper (8): On mechanism based PK/PD modelling for direct drug-ligand binding systems
12:30-12:50	Leon Aarons	Contributed paper (9): The role of modelling and simulation in the clinical development of anti-cancer agents
12:50-14:20	Lunch
	Oral session VI	Endogenous products/biotech products	chair: Rik Schoemaker
14:20-14:40	Niclas Jonsson	A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
14:40-15:00	Per-Henrik Zingmark	Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis
15:00-15:20	Christian Laveille	Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of estradiol in postmenopausal women
	Oral session VII	How to manage data around LOQ	chair: Leon Aarons
15:40-16:00	Dave Lunn	Graphical models and missing data
16:00-16:20	Vincent Duval	Contributed paper (10): Influence of LOQ on the PK parameters after an IV bolus dose
16:20-16:40	Ferdie Rombout	LOQ, a relic of the past?
16:40-17:00	Concluding remarks/preview PAGE 2002, Paris